| 
		U.S. FDA allows importing of 2 million baby formula cans from UK
		 Send a link to a friend 
		
  [May 25, 2022] By 
		Ahmed Aboulenein and Ananya Mariam Rajesh 
 WASHINGTON (Reuters) -The U.S. Food and 
		Drug Administration is easing regulations to allow infant formula 
		imports from Britain, a move it said on Tuesday would bring around 2 
		million cans onto empty shelves by June to ease a nationwide shortage.
 
 The FDA said it was "exercising enforcement discretion" to allow 
		Britain-based Kendal Nutricare to import certain infant formula products 
		under the Kendamil brand that it has no safety or nutrition concerns 
		over following an evaluation.
 
 "Under the agency's recent increased flexibilities regarding importation 
		of certain infant formula products, the company initially estimates that 
		about 2 million cans of infant formula are expected to land on U.S. 
		store shelves beginning in June," it said in a statement.
 
 Kendal has 40,000 cans in stock for immediate dispatch that the 
		Department of Health and Human Services is working on bringing into the 
		United States as soon as possible, the FDA said.
 
 
		
		 
		"We continue to do everything in our power as part of the 
		all-of-government efforts to ensure there's adequate infant formula 
		available wherever and whenever parents and caregivers need it," said 
		FDA Commissioner Robert Califf.
 
 The United States is experiencing one of the biggest infant formula 
		shortages in recent history after Abbott Laboratories in February 
		recalled some products including Similac and closed its manufacturing 
		plant in Sturgis, Michigan.
 
 Abbott, the biggest U.S. supplier of powder baby formula, shut its 
		facility after reports of bacterial infections among four infants. It 
		exacerbated a shortage among multiple manufacturers that began with 
		supply-chain issues tied to the coronavirus pandemic.
 
 
 [to top of second column]
 | 
            
			 
            
			Signage is seen outside of the Food and Drug Administration (FDA) 
			headquarters in White Oak, Maryland, U.S., August 29, 2020. 
			REUTERS/Andrew Kelly 
            
			
			
			 
            The FDA said it would allow the release of about 
			300,000 cans of Abbott's EleCare amino acid-based formula for 
			children who urgently need it to survive, on a case-by-case basis.
			
 EleCare was previously produced at the Sturgis facility but were not 
			part of the recall, the FDA said.
 
 Abbott plans to restart production at the facility on June 4, it 
			said in a statement, adding it would prioritize making EleCare and 
			supplying it on or about June 20. Abbott said it would provide the 
			formula to children in need for free.
 
 U.S. President Joe Biden's administration has sought to relieve the 
			shortage by importing emergency supplies from Europe, the first of 
			which arrived earlier this week. Biden invoked the Cold War-era 
			Defense Production Act to help boost supplies.
 
 The FDA said on Tuesday it was in discussion with other 
			manufacturers over additional supplies and that it would prioritize 
			products that demonstrate safety, nutritional adequacy, and are 
			available in large quantities.
 
 (Reporting by Ahmed Aboulenein in Washington and Ananya Mariam 
			Rajesh in Bengaluru; Additional reporting by Amruta Khandekar in 
			Bengaluru; Editing by Arun Koyyur and Richard Chang)
 
            [© 2022 Thomson Reuters. All rights 
				reserved.]This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content.
 
            
			
			 |